Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108476781> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2108476781 abstract "s) 2010, p. a2527. 17 Quin DI, Aparicio A, et al. T-WTe: Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC) − Final report: A California Cancer Consortium-led NCI/CTEPsponsored trial. J Clin Oncol (Meeting Abstracts) 2010. 18 Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007;18:522−8. 19 Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011;22:139−44. 20 Sanchez-Carbayo M, Cordon-Cardo C. Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer 2003;89:2172−7. 21 Pruthi RS, Nielsen M, Heathcote S, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int 2010;106:349−54. 22 Sonpavde G, Jian W, Liu H, et al. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009;27:391−9. What are the expected developments in the medical treatment of bladder cancer S297 23 Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010;28:1373−9. 24 Bellmunt J, Gonzalez-Larriba JL, Prior C, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 2011. doi: 10.1093/annonc/mdr023. 25 Dreicer R, Li H, Stein M, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009;115:4090−5. 26 Sridhar SS, Winquist E, Eisen A, et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs 2010. doi: 10.1007/s10637-010-9408-4. 27 Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol 2011;29:1525−30. 28 Bellmunt J: General Session Urothelial track. Computational Biology in Urothelial Cancer. Meeting Abstract ASCO-GU , 2011." @default.
- W2108476781 created "2016-06-24" @default.
- W2108476781 creator A5074756323 @default.
- W2108476781 date "2011-09-01" @default.
- W2108476781 modified "2023-09-26" @default.
- W2108476781 title "What are the expected developments in the medical treatment of bladder cancer" @default.
- W2108476781 cites W1483015025 @default.
- W2108476781 cites W1542114385 @default.
- W2108476781 cites W1554602088 @default.
- W2108476781 cites W1981323913 @default.
- W2108476781 cites W1991064094 @default.
- W2108476781 cites W1993184235 @default.
- W2108476781 cites W1993289360 @default.
- W2108476781 cites W2007665175 @default.
- W2108476781 cites W2018563247 @default.
- W2108476781 cites W2033248824 @default.
- W2108476781 cites W2039906674 @default.
- W2108476781 cites W2083209761 @default.
- W2108476781 cites W2102116016 @default.
- W2108476781 cites W2103192876 @default.
- W2108476781 cites W2104584442 @default.
- W2108476781 cites W2113425527 @default.
- W2108476781 cites W2121664617 @default.
- W2108476781 cites W2142915226 @default.
- W2108476781 cites W2147180151 @default.
- W2108476781 cites W2156845957 @default.
- W2108476781 cites W2161984323 @default.
- W2108476781 cites W2261887570 @default.
- W2108476781 cites W279678372 @default.
- W2108476781 cites W99289774 @default.
- W2108476781 cites W2025678147 @default.
- W2108476781 doi "https://doi.org/10.1016/s0959-8049(11)70177-0" @default.
- W2108476781 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21943989" @default.
- W2108476781 hasPublicationYear "2011" @default.
- W2108476781 type Work @default.
- W2108476781 sameAs 2108476781 @default.
- W2108476781 citedByCount "0" @default.
- W2108476781 crossrefType "journal-article" @default.
- W2108476781 hasAuthorship W2108476781A5074756323 @default.
- W2108476781 hasConcept C104317684 @default.
- W2108476781 hasConcept C104451858 @default.
- W2108476781 hasConcept C121608353 @default.
- W2108476781 hasConcept C126322002 @default.
- W2108476781 hasConcept C126894567 @default.
- W2108476781 hasConcept C134935766 @default.
- W2108476781 hasConcept C143998085 @default.
- W2108476781 hasConcept C185592680 @default.
- W2108476781 hasConcept C2775910329 @default.
- W2108476781 hasConcept C2776694085 @default.
- W2108476781 hasConcept C2778239845 @default.
- W2108476781 hasConcept C2779309665 @default.
- W2108476781 hasConcept C2779490328 @default.
- W2108476781 hasConcept C2780258809 @default.
- W2108476781 hasConcept C2780352672 @default.
- W2108476781 hasConcept C55493867 @default.
- W2108476781 hasConcept C71924100 @default.
- W2108476781 hasConceptScore W2108476781C104317684 @default.
- W2108476781 hasConceptScore W2108476781C104451858 @default.
- W2108476781 hasConceptScore W2108476781C121608353 @default.
- W2108476781 hasConceptScore W2108476781C126322002 @default.
- W2108476781 hasConceptScore W2108476781C126894567 @default.
- W2108476781 hasConceptScore W2108476781C134935766 @default.
- W2108476781 hasConceptScore W2108476781C143998085 @default.
- W2108476781 hasConceptScore W2108476781C185592680 @default.
- W2108476781 hasConceptScore W2108476781C2775910329 @default.
- W2108476781 hasConceptScore W2108476781C2776694085 @default.
- W2108476781 hasConceptScore W2108476781C2778239845 @default.
- W2108476781 hasConceptScore W2108476781C2779309665 @default.
- W2108476781 hasConceptScore W2108476781C2779490328 @default.
- W2108476781 hasConceptScore W2108476781C2780258809 @default.
- W2108476781 hasConceptScore W2108476781C2780352672 @default.
- W2108476781 hasConceptScore W2108476781C55493867 @default.
- W2108476781 hasConceptScore W2108476781C71924100 @default.
- W2108476781 hasLocation W21084767811 @default.
- W2108476781 hasLocation W21084767812 @default.
- W2108476781 hasOpenAccess W2108476781 @default.
- W2108476781 hasPrimaryLocation W21084767811 @default.
- W2108476781 hasRelatedWork W1979321249 @default.
- W2108476781 hasRelatedWork W2011500441 @default.
- W2108476781 hasRelatedWork W2013906813 @default.
- W2108476781 hasRelatedWork W2033100330 @default.
- W2108476781 hasRelatedWork W2063478695 @default.
- W2108476781 hasRelatedWork W2085905477 @default.
- W2108476781 hasRelatedWork W2099138165 @default.
- W2108476781 hasRelatedWork W2150771887 @default.
- W2108476781 hasRelatedWork W2474195589 @default.
- W2108476781 hasRelatedWork W2111135358 @default.
- W2108476781 isParatext "false" @default.
- W2108476781 isRetracted "false" @default.
- W2108476781 magId "2108476781" @default.
- W2108476781 workType "article" @default.